Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 8/20 | 0.37 |
| ▸ | MAOA | P21397 | 7/20 | 0.37 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14467181 | 0.71 | TDP1 (0.56) | LMNAHSD17B10BLMNPC1 | |
| SCHEMBL10784842 | 0.71 | — | — | |
| SCHEMBL2049798 | 0.68 | TAAR1 (0.36) | TAAR1MAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL12215973 | 0.66 | TSHR (0.36) | TAAR1MAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL13744051 | 0.65 | NOS3 (0.36) | TAAR1MAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL4192460 | 0.64 | NOS3 (0.35) | TAAR1MAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL4192456 | 0.64 | NOS2 (0.35) | TAAR1MAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL6311085 | 0.64 | NOS1 (0.45) | TAAR1MAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL6268220 | 0.64 | MAOB (0.50) | TAAR1MAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL11292416 | 0.64 | NOS1 (0.45) | TAAR1MAOBMAOAKDM1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0211746-B1 | PHENYL-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1990-05-23 | — | — | EP | claimed |
| EP-0211746-A1 | Phenyl-piperazine derivatives, process for their preparation and therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1987-02-25 | — | — | EP | claimed |
| US-6603003-B2 | Reacting ester with substituted or unsubstituted ethylenediamine to give 3,4-dehydropiperazine-2-one and reacting 3,4-dehydropiperazine-2-one with reducing agent to yield piperazine derivative | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2003-08-05 | — | — | US | disclosed |
| EP-1202738-A4 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020095038-A1 | Novel method for the preparation of piperazine and its derivatives | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2002-07-18 | — | — | US | disclosed |
| WO-2002038552-A1 | A NOVEL METHOD FOR THE PREPARATION OF PIPERAZINE AND ITS DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2002-05-16 | — | — | WO | disclosed |
| EP-1202738-A1 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6177429-B1 | SELECTIVE NEUROPEPTIDE Y (NPY) RECEPTOR ANTAGONISTS FOR PROMOTING WEIGHT LOSS AND TREATMENT OF EATING DISORDERS; ANOREXIGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2001-01-23 | — | — | US | disclosed |
| WO-2000078319-A1 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0211746-B1 | PHENYL-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1990-05-23 | — | — | EP | disclosed |
| EP-0211746-B1 | PHENYL-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1990-05-23 | — | — | EP | disclosed |
| US-4912110-A | Antidepressive substituted phenylpiperazine compounds | LABORATOIRE L. LAFTON (FR) | 1990-03-27 | — | — | US | disclosed |
| EP-0211746-A1 | Phenyl-piperazine derivatives, process for their preparation and therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095038-A1 | Novel method for the preparation of piperazine and its derivatives | DHPS, DRD4, CYP2E1 | TAAR1 496/4885MAOB 296/4885MAOA 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.